Aquestive Therapeutics, Inc. (AQST) News

Aquestive Therapeutics, Inc. (AQST): $0.95

0.02 (+1.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter AQST News Items

AQST News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AQST News Highlights

  • For AQST, its 30 day story count is now at 5.
  • Over the past 14 days, the trend for AQST's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about AQST are NOV and BMO.

Latest AQST News From Around the Web

Below are the latest news stories about AQUESTIVE THERAPEUTICS INC that investors may wish to consider to help them evaluate AQST as an investment opportunity.

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the management team will participate in the two upcoming investor conferences as follows: Piper Sandler 34th Annual Healthcare Conference: presentation at 1:50 pm ET on Wednesday, November 30thA.G.P.’s Virtual Biotech Conference: available for investo

Yahoo | November 15, 2022

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting

WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its completed pharmacokinetic studies of AQST-109 (epinephrine sublingual film) at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting, which will be held from November 10-14, in

Yahoo | November 9, 2022

Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities

JMP Securities analyst Jason Butler reiterated a Buy rating on Aquestive Therapeutics (AQST - Research Report) today and set a price target of $7.00. The company's shares closed today at $0.84.Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Athira Pharma, and Cytokinetics. According to TipRanks, Butler has an average return of -7.9% and a 38.62% success rate on recommended stocks. Aquestive Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.00, implying a 614.29% upside from current levels. In a report released today, BMO Capital also maintained a Buy rating on the stock with a $4.00 price target.

Ryan Adist on TipRanks | November 2, 2022

Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 1, 2022

Aquestive Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Reported positive data from EPIPHAST II trial comparing AQST-109 (epinephrine sublingual film) to EpiPen® 0.3mg (single dose) and AQST-109 to epi 0.3mg IM injection (repeat dose)Scheduled End-of-Phase 2 (EoP2) meeting with FDA on AQST-109 for fourth quarter 2022Generated over $25 million in near-term non-dilutive funding through multiple transactionsAnnounces strategic decision to explore US out-licensing opportunities for Libervant (diazepam buccal film)Confirms full-year revenue and earnings g

Yahoo | November 1, 2022

Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.

WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today a transaction to license Sympazan® (clobazam) oral film to Otter Pharmaceuticals, LLC, a subsidiary of Assertio Holdings, Inc. (“Assertio”) (NASDAQ: ASRT), a specialty pharmaceutical company offering differentiated products to patients. Sympazan (clobazam)

Yahoo | October 27, 2022

Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.

Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to patients, today announced a transaction to acquire an exclusive license for Sympazan® (clobazam) oral film from Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq: AQST

Yahoo | October 27, 2022

Aquestive Therapeutics Announces Positive Decision in States’ Suboxone Antitrust Lawsuit on All Claims

WARREN, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, announced today that the United States District Court for the Eastern District of Pennsylvania entered an order on October 19, 2022 dismissing all claims against Aquestive in the Suboxone antitrust lawsuit brought by a group of States’ Attorneys General against Indivior I

Yahoo | October 24, 2022

Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET

WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients’ problems through simplifying complex delivery methods, today announced that it will report results for third quarter ended September 30, 2022, and provide an update on recent developments in its business after market close on Tuesday, November 1, 2022. Management will host a conference call for investors at 8:00 a.m. ET on We

Yahoo | October 19, 2022

JMP Securities Sticks to Their Buy Rating for Aquestive Therapeutics (AQST)

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on Aquestive Therapeutics (AQST - Research Report), with a price target of $7.00. The company's shares opened today at $1.04.Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Cytokinetics, and Gamida Cell. According to TipRanks, Butler has an average return of -6.1% and a 38.52% success rate on recommended stocks. Currently, the analyst consensus on Aquestive Therapeutics is a Strong Buy with an average price target of $6.50, which is a 525.00% upside from current levels.

Christine Brown on TipRanks | October 11, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5645 seconds.